TY  - JOUR
AU  - Pose, Elisa
AU  - Napoleone, Laura
AU  - Amin, Ahmed
AU  - Campion, Daniela
AU  - Jimenez, César
AU  - Piano, Salvatore
AU  - Roux, Olivier
AU  - Uschner, Frank Erhard
AU  - de Wit, Koos
AU  - Zaccherini, Giacomo
AU  - Alessandria, Carlo
AU  - Angeli, Paolo
AU  - Bernardi, Mauro
AU  - Beuers, Ulrich
AU  - Caraceni, Paolo
AU  - Durand, François
AU  - Mookerjee, Rajeshwar P
AU  - Trebicka, Jonel
AU  - Vargas, Victor
AU  - Andrade, Raúl J
AU  - Carol, Marta
AU  - Pich, Judit
AU  - Ferrero, Juan
AU  - Domenech, Gema
AU  - Llopis, Marta
AU  - Torres, Ferran
AU  - Kamath, Patrick S
AU  - Abraldes, Juan G
AU  - Solà, Elsa
AU  - Ginès, Pere
PY  - 2019
DO  - 10.1016/S2468-1253(19)30320-6
UR  - http://hdl.handle.net/10668/14689
T2  - The lancet. Gastroenterology & hepatology
AB  - Statins have beneficial effects on intrahepatic circulation and decrease portal hypertension and rifaximin modulates the gut microbiome and might prevent bacterial translocation in patients with cirrhosis. Therefore, this drug combination might be of...
LA  - en
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Follow-Up Studies
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Hypertension, Portal
KW  - Liver Cirrhosis
KW  - Portal Pressure
KW  - Rifaximin
KW  - Simvastatin
KW  - Treatment Outcome
TI  - Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
TY  - research article
VL  - 5
ER  -